Harpoon Therapeutics, Inc. HARP
23.01 +23.01
Day range unavailable
52-week range unavailable
News
businesswire.com Merck Completes Acquisition of Harpoon Therapeutics, Inc. RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).…
businesswire.com HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon…
investopedia.com Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio Shares of Harpoon Therapeutics Inc. (HARP) more than doubled Monday after Merck & Co. (MRK) agreed to buy the cancer drug researcher for about $680 million.
prnewswire.com Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click…
businesswire.com HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Harpoon Therapeutics, Inc. (NASDAQ: HARP) to Merck for $23.00 per share in cash is fair…
benzinga.com Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.…
investorplace.com Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today? Harpoon Therapeutics (NASDAQ: HARP ) stock is rocketing higher on Monday after Merck (NYSE: MRK ) announced plans to acquire the company. Merck is offering $23 per share for HARP stock.
wsj.com Merck to Buy Harpoon Therapeutics for $680 Million Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.- reuters.com Merck to buy Harpoon Therapeutics for $680 million Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.
businesswire.com Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced…
proactiveinvestors.com Merck close to acquiring cancer specialist Harpoon Therapeutics Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value…
reuters.com Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.
globenewswire.com Harpoon Therapeutics Strengthens Leadership Team James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif.
globenewswire.com Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced…
globenewswire.com Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) • HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to…
zacks.com 5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
zacks.com Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross? Harpoon Therapeutics, Inc. (HARP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HARP's 50-day simple moving average broke out…
zacks.com Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock? Harpoon Therapeutics, Inc. (HARP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near…
zacks.com Best Momentum Stock to Buy for December 5th PDD, HARP and LEU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 5, 2023.
zacks.com Is it a Good Idea to Invest in Harpoon (HARP) Stock Now? Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.
zacks.com Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade The consensus price target hints at a 40.5% upside potential for Harpoon Therapeutics, Inc. (HARP). While empirical research shows that this sought-after metric is hardly effective, an upward trend…
benzinga.com Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.
benzinga.com Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 116 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 - benzinga.com Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
- benzinga.com Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 930 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 340 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 507 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 574 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 529 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com 95 Biggest Movers From Friday Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.51.